Carl Zeiss Meditec ((GB:0DHC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The clinical study titled ‘Evaluation of Refractive Outcomes in Patients Undergoing PRESBYOND Using the MEL90 Excimer Laser’ aims to assess vision improvements in individuals aged 45 to 65 with presbyopia, a common age-related condition affecting near vision. Conducted by Carl Zeiss Meditec AG, the study seeks to determine the effectiveness of the PRESBYOND laser eye surgery method in enhancing distance, intermediate, and near vision, as well as patient satisfaction post-surgery.
The intervention involves the use of the MEL90 excimer laser for the PRESBYOND procedure, a personalized laser eye surgery designed to correct presbyopia. The treatment involves creating a corneal flap and reshaping the cornea to improve vision across various distances, allowing the brain to merge images for better visual tasks without glasses.
This observational study follows a cohort model with a prospective time perspective. Participants will undergo the same treatment without a comparison group, attending seven visits over six months to monitor outcomes and satisfaction.
The study is set to begin recruitment on April 29, 2025, with the same date marking the last update submission. The primary completion and estimated study completion dates are yet to be announced, indicating the study’s early phase.
From a market perspective, this study could positively influence Carl Zeiss Meditec’s stock performance by showcasing advancements in presbyopia treatment, potentially enhancing investor confidence. As the company competes in the ophthalmic technology sector, successful outcomes may strengthen its market position against competitors.
The study is ongoing, with further details accessible on the ClinicalTrials portal.